Combination therapy of avelumab and axitinib in a patient with renal cell carcinoma in a good prognostic group - case report
2022
Abstract
Therapy of metastatic renal cell carcinoma has developed significantly in the last decade. At present, we have the opportunity to use targeted therapy, immunotherapy, or a combination thereof.
In the case of patients in a good prognostic group, it is now possible in the Czech Republic to use a combination of immunotherapy with targeted therapy - avelumab and axitinib. The following article describes our first experience with this combination therapy in routine clinical practice.
